EUROPEAN RENAL ASSOCIATION - EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION    
 
Services How to use the platform Build a poster MANAGE ORDERS FAQs Contact HOMEPAGE
 
 
   
Discussion forum - 49th ERA-EDTA Congress
    Topic - Primary and secondary glomerulonephritis I

If you are already registered in PosterSessionOnline, enter your e-mail and click on LOGIN. Otherwise click on REGISTER.

 

Poster: 422
Visits: 637
Title: PAX-2 PROTEIN AS A MARKER OF DEDIFFERENTIATION OF PODOCYTES IN PATIENTS WITH CHRONIC GLOMERULONEPHRITIS (CGN): ASSOCIATION WITH CLINICAL AND MORPHOLOGICAL MARKERS OF GLOMERULAR DEMAGE AND NEPHROSCLEROSIS
Authors: Mikhail Shvetsov , Olga Popova, Natalia Chebotareva, Aleksey Ivanov, Irina Bobkova
Centre: I.M. Sechenov First Moscow State Medical University

You must be registered to reply or comment.

PAX-2 PROTEIN AS A MARKER OF DEDIFFERENTIATION OF PODOCYTES IN PATIENTS WITH CHRONIC GLOMERULONEPHRITIS (CGN): ASSOCIATION WITH CLINICAL AND MORPHOLOGICAL MARKERS OF GLOMERULAR DEMAGE AND NEPHROSCLEROSIS

Mikhail Shvetsov
Thread initiator
Subspeciality
Reg: 4/23/2009 4:34:00 AM

Comment# 1

I invite healthcare professionals to open debate around the issues raised in my poster, both those relating to research and to clinical practice.

Comment added on 5/9/2012 7:22:00 PM 
     
You must be registered to reply or comment.




Most viewed poster for this congress
Poster: 424
Visits: 2636
Title: Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Glomerulonephritides: an Immunohystochemical expression analysis
Authors: Giuseppe Coppolino ,
Centre: Chair of Nephrology, University Magna Graecia of Catanzaro, Catanzaro, Italy


Poster most viewed in this topic
Poster: 291
Visits: 1109
Title: MEMBRANOUS GLOMERULONEPHRITIS AND ANTI-PHOSPHOLIPASE A2-RECEPTOR ANTIBODY TESTING: USEFUL TOOL IN IN ROUTINE CLINICAL PRACTICE
Authors: Ulf Schnermarck ,
Centre: University Hospital Munich, Ludwig-Maximilians Universitiy Munich


 View Poster Gallery
 Back to congress home
 Other Congresses


 
 
  About us  |  Terms and Conditions  |  Special Access